Outcome predictions for patients with metastatic prostate cancer

Seminars in Urologic Oncology

Volumn 20, Issue 2, 2002, Pages 155-163

  Smaletz, Oren ^a   Scher, Howard I ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Neoplasm metastasis; Prognosis; Prostatic neoplasms; Survival

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYTOTOXIC AGENT; DIETHYLSTILBESTROL; DOXORUBICIN; EDATREXATE; EFLORNITHINE; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GALLIUM NITRATE; GEMCITABINE; GONADORELIN DERIVATIVE; GOSERELIN; HYDROCORTISONE; INTERFERON; ISOTRETINOIN; LEUPRORELIN; MEGESTROL ACETATE; MITOMYCIN C; MITOXANTRONE; NILUTAMIDE; RETINOIC ACID; RHENIUM 186; SURAMIN; TRIMETREXATE; VINBLASTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; METASTASIS; ORCHIECTOMY; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036097509     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.32938     Document Type: Article

References (36)

1. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
2. Clinical states in prostate cancer: Towards a dynamic model of disease progression
3. Statistical aspects of prognostic factor studies in oncology
4. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
5. Orchiectomy versus Goserelin and Flutamide In the treatment of newly diagnosed metastatic prostate cancer
6. Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a Cooperative Intergroup Study (INT 0036)
7. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
8. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from 2 European Organizations for Research on Treatment of Cancer Trials
9. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
10. Analysis of prognostic factors in men with metastatic prostate cancer
11. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials
12. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer
13. Analysis of prognostic factors in disseminated prostatic cancer: An update
14. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
15. Docetaxel (Taxotere) in hormone-refractory prostate cancer
16. Phase II randomized trial of weekly paclitaxel (Taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP)
17. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
18. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial
19. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
20. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
21. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer
22. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
23. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
24. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival
25. Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer
26. Prognostic factors in patients with advanced stage prostate cancer
27. Prognostic factors in hormone-resistant progressing cancer of the prostate
28. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment
29. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer
30. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
31. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: An analysis of Cancer and Leukemia Group B Study 9181 of megestrol acetate
32. A prognostic score for hormone-refractory prostate cancer: Analysis of two Cancer and Leukemia Group B studies
33. Prognostic factors for survival in patients with hormone refractory bidimensionally measurable metastatic prostatic carcinoma treated with single agent chemotherapy
34. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
35. A nomogram for overall survival of patients with castrate-metastatic prostate cancer (PC)